Skin Disorders

Replicine™ Bioactive Keratin for Wounds Caused by Skin Disorders

Replicine™ Bioactive Keratin is Critical to Wound Healing in Epidermolysis Bullosa (EB)

Wound care for patients with a rare genetic disorder, EB, represents a therapeutic challenge. EB results from a genetic mutation in at least one of 18 genes involved with proteins in the epidermis, dermis, or basement membrane.1 These proteins form the major component of the anchoring fibrils, providing support between dermis and basal lamina.2

People with Recessive Dystrophic EB, a major subtype and the most severe form of EB, have insufficient or dysfunctional structural collagen VII protein. Their skin is weak and demonstrates poor adhesion of the epidermis to the dermis. They are therefore susceptible to resultant blistering from minor mechanical friction or trauma, poor skin durability, and slow healing.2

The fact is, EB is highly problematic to treat, and treatment options are limited. Wound products that are atraumatic when applied to normal skin can be damaging to the skin of those affected by EB.3

KeragelT® Is Especially Beneficial For EB 

KeragelT® is currently available for EB patients. The mechanism and use of KeragelT® in the treatment of EB is supported by data from multiple clinical studies showing faster healing and substantial improvement in skin robustness.3-6 KeragelT® enhances keratinocyte migration and proliferation rates in wounds and accelerates healing in this challenging patient population.2 In addition, the coating of KeragelT® keeps the nerve endings moist. This aids healing and also keeps air off the wound, which can help with pain that this might normally cause. It can also reduce itch and the subsequent damage that would occur from scratching, especially in EB patients.3,6

Significant Overall Improvements With Replicine™ Bioactive Keratin in EB

In a case study of a patient 11 years of age with recessive dystrophic epidermolysis bulosa (RDEB), treatment with Replicine™ Bioactive Keratin resulted in a significant improvement and more robust skin with reduced blistering, resulting in improved comfort and overall appearance. The keratin treatment allowed the patient to discontinue use of secondary dressings, offering a significant improvement in quality of life.5


Consistent blistering in upper shoulder and neck area of a patient 11 years of age with EB.5 Regular use with KeragelT demonstrates healed blisters, less frequent formation, and more robust skin after 9 months.5

Faster Healing and More Resilient Healed Skin

A 10-case study series in patients with different types of EB and a range of acute and chronic wounds demonstrated faster healing and more resilient healed skin resulting from treatment with Replicine™ Bioactive Keratin. All patients and their caregivers found Replicine™ Bioactive Keratin to be easy to use and reported no adverse events. In addition, patients’ quality of life improved with increased mobility, reduction of itching, and reduced discomfort from heat.3


Before treatment.3 After 4 weeks of Replicine™ Bioactive Keratin treatment, epithelialization is observed at the wound margins and the wound area is reduced.3 After 20 weeks of treatment, wounds are almost completely epithelialized.3

Profound Demonstrations of Healing in EB With Replicine™ Bioactive Keratin

In one study, KeragelT® was applied directly to the wounded areas on the left hand and left foot of an infant; the right foot and hand continued with standard care control. The treated skin showed faster healing and substantial improvement in skin robustness, as well as a decreased number of blisters. The patient’s dexterity and quality of life was improved, and overall cost of care was significantly reduced.2



Control right foot after 4 months
showing severe blistering.2
KeragelT®-treated left foot after 4 months
demonstrating less severe and frequent blistering.2

Before treatment.3 Significant improvements after 4 days
of treatment with Replicine™
Bioactive Keratin.3

Before treatment.3 After 2 weeks of Replicine™
Bioactive Keratin treatment,
the wound is essentially healed.3
After 4 weeks of treatment,
the fingers are strong enough
to forego regular protective


1.Lucky, AW, Koplen B, Kelley-Mancuso G. National Organization for Rare Disorders (NORD). Accessed August 17, 2018. 2. Kirsner RS, Cassidy S, Marsh C, et al. Use of a keratin-based wound dressing in the management of wounds in a patient with recessive dystrophic epidermolysis bullosa. Adv Skin Wound Care. 2012;25(9):400-403. 3. Denyer J, Marsh C, Kirsner RS. Keratin gel in the management of Epidermolysis bullosa. J Wound Care. 2015;24(10):446-450. 4. Tadini G, Marsh C, Kirsner R. An evaluation of a keratin gel to accelerate healing and improve care for epidermolysis bullosa patients. Poster presented at: Symposium on Advanced Wound Care, San Antonio, TX; April 2015. 5. Than MP, Smith RA, Cassidy S, et al. Use of a keratin-based hydrogel in the management of recessive dystrophic epidermolysis bullosa. J Derm Treat. 2013;24(4):290-291. 6. Sussman G. Advances in wound dressing technology. Wounds Int. 2013;4(4):12-14.